Modulation of Toll-like Receptor 4 or Other TLRs for Treatment or Prevention of Bone Loss

Reference #:

2002-226

Inventors/Contributors

Jeffrey L. Platt M.D., Geoffrey B. Johnson M.D., Ph.D.

Description

Mayo Clinic researchers have identified the use of biological, pharmacological or saccharide intervention, genetic modification or selection, for antagonist or modulation of Toll-like receptor 4 (TLR4) or other TLRs for the increase and/or maintenance of bone density, osteoporosis, Paget's disease, or any disease or condition in which bone loss is a factor.

Patent Status

Pending